Patent Application
20220031936
The present disclosure relates to drug-delivery systems, and in particular to drug-delivery systems including drug-delivery device assemblies that are attachable to an infusion hub with a pre-inserted cannula. The drug-delivery device assemblies disclosed herein can deliver doses of a secondary drug through the pre-inserted cannula of the infusion hub.
Individuals with chronic medical conditions often use infusion sets to deliver medication from a pump to an insertion site on the body. For example, patients with insulin-dependent diabetes (also referred to simply as “diabetes”) who use continuous insulin infusion therapy often use insulin infusion sets to deliver insulin through an insertion site on the abdomen, thigh, arm, lower back, or buttock. The infusion set carries insulin from the pump through a tube to a needle or cannula mounted on an insertion hub and inserted into a subcutaneous space on the patient's body.
Patients using an infusion set to deliver a medication to the insertion site may desire delivery of a second medication in addition to the primary medication. For example, patients with insulin-dependent diabetes may experience hypoglycemic events in which their glucose levels drop too low. This can happen, for instance, when the patient administers too much insulin, when the patient exercises, when the patient has not eaten for an extended time, or when the patient is asleep for an extended time. If the hypoglycemic event is mild, it may be treated by ingesting fast-acting carbohydrates. However, in cases of severe hypoglycemia and/or when the patient is unable to eat or drink, it may be treated by administering one or more therapeutic agents operative to raise a patient's glucose levels (e.g., blood glucose levels or interstitial glucose levels), such as glucagon, glucagon analogs, glucagon derivatives (simply referred to herein as “glucagon”).
Glucagon may be administered using an emergency glucagon kit. Such emergency kits may comprise an injection device that stores a single, full dose of glucagon and, when pressed against a portion of the patient's body and activated, injects the entire dose via a subcutaneous needle injection. Alternatively, such emergency kits may comprise one or more vials of glucagon and a syringe that the patient may manually fill and inject. However, these emergency glucagon kits may suffer from several disadvantages.
For example, patients with diabetes are generally already burdened by the need to carry and manage various devices and supplies, such as a blood-glucose monitor (BGM), a continuous-glucose monitor (CGM), insulin pump lancing device, spare lancets, infusion sets, pump cartridges, alcohol swabs, adhesives, syringes, insulin, and/or fast-acting carbohydrates. The cognitive and emotional load of carrying a separate emergency glucagon kit in addition to all these devices and supplies may take a toll, and many patients may refuse or forget to carry an emergency glucagon kit with them.
Furthermore, emergency glucagon kits require a separate subcutaneous injection to administer glucagon (i.e., separate from a pre-inserted infusion hub delivering the primary drug), thereby requiring another injection site on the patient and increasing the risk of additional pain, infection, or other complications.
Therefore, a need exists for a delivery device assembly that is attachable to an infusion hub and is configured to deliver a secondary drug through a pre-inserted cannula.
The present disclosure relates to drug-delivery systems including drug-delivery device assemblies that are attachable to an infusion hub with a pre-inserted cannula. In illustrated embodiments, such devices allow patients with diabetes to administer a secondary drug as needed via the cannula of the infusion hub. In some embodiments, the device is low-profile, discrete, and easy-to-assemble onto the infusion set hub. In some embodiments, such devices are relatively non-intrusive and easy-to-carry, increasing the likelihood that the patient will carry the device and thereby facilitating a discrete way to administer a secondary drug for convenience and for emergency situations.
In the illustrated embodiments, the devices are configured to administer the secondary drug through the same cannula of the infusion hub used to deliver the primary drug. Alternatively, the infusion hub may include a second pre-inserted cannula for delivery of the secondary drug in addition to the first pre-inserted cannula for delivery of the primary drug.
In addition to glucagon, the drug-delivery device assemblies of the present disclosure may be used to deliver any suitable type of secondary drugs. For example, such drug-delivery device assemblies may be used to deliver a different type of insulin than the insulin already delivered through the infusion hub. More specifically, the infusion hub may be connected to a pump and reservoir designed to deliver basal insulin (the primary drug), and the drug-delivery device assembly of the present disclosure may deliver meal-time bolus insulin (the secondary drug). As another example, drug-delivery device assemblies of the present disclosure may be used to deliver a nonsteroidal anti-inflammatory drug (NSAID). NSAIDs are a class of drugs that reduce pain, decrease fever, reduce the likelihood of blood clots, and decrease inflammation. Doses of NSAIDs to an infusion set injection site may aid in reducing or delaying inflammation in or around the site, which in turn may increase the effectiveness or prolong the life of the injection site. NSAIDs may also reduce pain in the injection site. As another example, when an infusion set is being used to deliver a chemotherapy agent for treatment of cancer, the drug delivery device assemblies of the present disclosure may contain an antiemetic (anti-nausea) drug for delivery as a secondary drug.
In one aspect, the present disclosure relates to a drug-delivery device assembly comprising: a manifold configured to detachably couple with an infusion hub configured to subcutaneously deliver a primary drug into a patient's body, the manifold defining a fluid channel that connects a proximal surface of the manifold with a distal surface of the manifold; a screw cap having an internal surface that, when the screw cap is coupled to the manifold, opposes the distal surface of the manifold; and a flexible drug reservoir disposed between the distal surface of the manifold and the internal surface of the screw cap, the flexible drug reservoir configured to store a secondary drug, wherein the screw cap is configured to couple to the manifold using screw threads such that rotation of the screw cap relative to the manifold causes a distance between the internal surface of the screw cap and the distal surface of the manifold to decrease, thereby compressing the flexible drug reservoir such that the secondary drug is expelled from the reservoir, through the fluid channel in the manifold, and through the infusion hub.
In some embodiments, the infusion hub is configured to deliver the primary drug via a lumen inserted subcutaneously into the patient's body; and compression of the flexible drug reservoir causes the secondary drug to be delivered subcutaneously into the patient's body via the same lumen.
In some embodiments, the infusion hub comprises a hub septum; the proximal surface of the manifold comprises a hub-mate septum; and the drug-delivery device assembly further comprises a needle hub having a staked double-pointed needle with a proximal end and a distal end, wherein, when the drug-delivery device assembly is coupled with the infusion hub, the distal end of the double-pointed needle is configured to pierce the hub-mate septum and the proximal end of the double-pointed needle is configured to pierce the hub septum, thereby providing a passage for the secondary drug to flow from the drug-delivery device assembly into the infusion hub.
In some embodiments, the drug-delivery device assembly further comprises a valve disposed between the flexible drug reservoir and the fluid channel in the manifold, the valve being configured to prevent the secondary drug from flowing into the fluid channel until the flexible drug reservoir is compressed by rotation of the screw cap relative to the manifold.
In some embodiments, the flexible drug reservoir comprises at least one rigid plate affixed to a flexible film using a fluid-tight seal. In some embodiments, the rigid plate defines a first fluid passage configured to connect with the fluid channel in the manifold. In some embodiments, the rigid plate defines a second fluid passage for filling the flexible drug reservoir, the second fluid passage being sealed with a removable stopper when the drug reservoir is not being filled.
In some embodiments, the manifold defines a second fluid passage for filling the flexible drug reservoir.
In some embodiments, the flexible drug reservoir stores multiple doses of the secondary drug.
In some embodiments, the drug-delivery device assembly further comprises a locking mechanism that prevents rotation of the screw cap relative to the manifold unless the mechanism is unlocked. The locking mechanism may comprise a spring-loaded pin.
In some embodiments, the drug-delivery device assembly further comprises a wireless antenna and a circuit board communicably coupled to the wireless antenna, wherein the circuit board is configured to control rotation of the screw cap relative to the manifold in accordance with one or more wireless signals received via the wireless antenna. Some of these embodiments further comprises a screw-cap subassembly having a nut and a torsion spring coupled to the screw cap and the nut, the torsion spring being held in a pre-loaded state by a release mechanism controlled by the circuit board, wherein the circuit board is configured to release the release mechanism in accordance with the one or more wireless signals such that stored energy in the pre-loaded torsion spring causes the nut to rotate relative to the screw cap. The release mechanism may comprise at least one of an electrically-actuated mechanical switch, an electrically-actuated gear, and a fuse pin. In some of these embodiments, rotation of the nut relative to the screw cap causes the nut to translate proximally so as to compress the flexible drug reservoir. In some of these embodiments, rotation of the nut relative to the screw cap causes a piston in the screw-cap subassembly to translate proximally so as to compress the flexible drug reservoir.
In some embodiments, the primary drug is at least one of an insulin and an insulin analog, and the secondary drug is at least one of glucagon and a nonsteroidal anti-inflammatory drug (NSAID).
In some of these embodiments, the flexible drug reservoir has two or more compartments, each filled with a different drug constituent; and the two or more compartments are separated from one another by one or more frangible seals such that, when the screw cap is rotated relative to the manifold, positive pressure generated by compression of at least one of the compartments causes the one or more frangible seals to break, thereby allowing the drug constituents to mix.
In another aspect, the present disclosure relates to a method for using a drug-delivery device assembly to deliver a secondary drug to a patient's body via an infusion hub positioned on the patient's body for delivering a primary drug, the infusion hub having a hub septum, the method comprising: providing the drug-delivery device assembly, the assembly comprising a manifold defining a fluid channel for delivering the secondary drug, the fluid channel being connected to a hub-mate septum on a proximal surface of the manifold, and a needle hub separate from the manifold, the needle hub having a staked double-pointed needle with a proximal end and a distal end; pushing the needle hub against the proximal surface of the manifold such that the distal end of the double-pointed needle pierces the hub-mate septum of the manifold; pushing the manifold and the needle hub against the infusion hub such that the proximal end of the double-pointed needle pierces the hub septum of the infusion hub, thereby providing a passage for the secondary drug to flow from the fluid channel into the infusion hub.
In some embodiments, the drug-delivery device assembly further comprises a screw cap with an interior surface coupled to the manifold using screw threads, and a flexible drug reservoir disposed between the interior surface of the screw cap and the manifold; wherein the method further comprises rotating the screw cap relative to the manifold to cause a distance between the internal surface of the screw cap and the manifold to decrease, thereby compressing the flexible drug reservoir such that the secondary drug is expelled from the reservoir, through the fluid channel in the manifold and the double-pointed needle in the needle hub, and through the infusion hub.
According to another embodiment of the present disclosure, a drug-delivery device assembly includes a manifold having a drug channel. The manifold is configured to detachably couple with an infusion hub, and the infusion hub is configured to subcutaneously deliver a primary drug into a patient's body. The drug-delivery device assembly further includes a drug reservoir that is configured to store a secondary drug. The drug reservoir is disposed within the manifold and is coupled to the drug channel. A drug plunger is movable relative to the drug reservoir. A biasing member is configured to move away from a loaded state and toward an unloaded state to move the drug plunger relative to the drug reservoir and force the secondary drug from the drug reservoir, through the drug channel, through the infusion hub, and into the patient's body.
According to yet another embodiment of the present disclosure, a drug-delivery device assembly includes an infusion hub that is configured to receive a primary drug from a primary drug-delivery device and deliver the primary drug into a patient's body. A manifold is configured to detachably couple with the infusion hub, and the manifold includes a drug channel. The drug-delivery device assembly further includes a drug reservoir that is configured to store a secondary drug, and the drug reservoir is disposed within the manifold and coupled to the drug channel. A drug plunger is movable relative to the drug reservoir. A biasing member is configured to move away from a loaded state and toward an unloaded state to move the drug plunger relative to the drug reservoir and force the secondary drug from the drug reservoir, through the drug channel, through the infusion hub, and into the patient's body.
The above mentioned and other features of this present disclosure, and the manner of attaining them, will become more apparent and will be better understood by reference to the following description of embodiments of the present disclosure taken in conjunction with the accompanying drawings, wherein:
Corresponding reference characters indicate corresponding parts throughout the several views. Although the exemplification set out herein illustrates embodiments of the present disclosure, in several forms, the embodiments disclosed below are not intended to be exhaustive or to be construed as limiting the scope of the invention to the precise forms disclosed.
The present disclosure relates to drug-delivery systems including drug-delivery device assemblies, or “hub mates,” that attach to an infusion hub. The infusion hub may be connected to a source of a primary drug and may be configured to deliver the primary drug subcutaneously into the patient's body via a lumen of a needle or cannula inserted into an infusion site. The drug-delivery device assemblies may carry and deliver a secondary drug into the patient's body via the needle or cannula of the infusion hub together with any of the primary drug that is also present in the infusion hub or at a time when delivery of the primary drug through the needle or cannula is halted. The primary drug or secondary drug may include one or more therapeutic agents such as insulins, insulin analogs such as insulin lispro or insulin glargine, insulin derivatives, GLP-1 receptor agonists such as dulaglutide or liraglutide, gastric inhibitory polypeptide (GIP), GIP analogs, GIP derivatives, oxyntomodulin analogs, oxyntomodulin derivatives, therapeutic antibodies such as IL-23 antibody analogs or derivatives, such as mirikizumab, IL-17 antibody analogs or derivatives, such as ixekizumab, therapeutic agents for pain related treatments, such as galcanezumab or lasmiditan, chemotherapy drugs, or any other therapeutic agent that is capable of delivery by an infusion hub. The primary drug or secondary drug may be formulated with one or more excipients.
In exemplary embodiments disclosed herein, the secondary drug includes one or more therapeutic agents such as those designed to raise a patient's glucose levels (such as glucagon), a type of insulin different than a primary insulin being delivered through the infusion hub, NSAIDs, antiemetic (anti-nausea) drugs, or any other suitable therapeutic agent that is capable of delivery through an infusion hub. Exemplary secondary drugs include, for example, meloxicam, bromfenac sodium, acetylsalicylic acid, salicylic acid, paracetamol, heparin, and dexamethasone, although other suitable drugs may be provided for delivery by the drug-delivery device assemblies of the present disclosure.
In some embodiments, the drug delivery device assembly delivers a secondary drug that is a different type of insulin than an insulin normally being delivered through the infusion set hub. For instance, the infusion set hub may be connected to a pump (
Referring initially to
Referring now to
Flexible drug reservoir 206 may be made from a thin, flexible, drug-compatible film, such as cyclic olefin copolymer (COC), cyclic olefin polymers (COP), high-density polyethylene (HDPE), and/or polychlorotrifluoroethylene (PCTFE). Other materials may also be used, depending upon the drug stored therein. In some embodiments, drug reservoir 206 may comprise a single compartment that stores a single type of drug. In other embodiments, drug reservoir 206 may comprise two or more compartments, each filled with a different drug constituent. For example, reservoir 206 may comprise a first compartment stacked on top of (e.g., located distal to) a second compartment, wherein the first compartment stores a liquid diluent and the second compartment stores a lyophilized drug powder, such as glucagon powder. This arrangement is illustrated by the horizontal dashed line drawn through the center of reservoir 206 in
Drug reservoir 206 may be heat-sealed or otherwise affixed in a fluid-tight manner to valve capture plate 224. In this way, valve capture plate 224 provides a rigid bottom surface on which flexible drug reservoir 206 rests. Valve capture plate 224 and manifold 208 may define a through-hole 228 which may be used to fill reservoir 206. After filling, through-hole 228 may be stoppered by an elastic stopper 230.
Infusion set hub 216 is connected to a source of a primary drug (e.g., device 106 of
To dispense the secondary drug from the drug reservoir 206, a user (e.g., the patient, a caregiver, and/or a healthcare professional) rotates screw cap 202 relative to manifold 208. Due to the engagement between internal screw threads 204 and external threads 210, rotation of the screw cap causes a distance between the internal surface of the screw cap 202 and the distal surface of manifold 208 to decrease. This decrease in distance compresses the flexible drug reservoir 206 such that the secondary drug is expelled from the reservoir 206, through valve 226, fluid channel 232, hub-mate septum 234, double-staked needle 214, hub septum 218, secondary drug channel 238, and lumen 220, and into the patient's body. The minimum dose that can be dispensed from assembly 200 will depend upon the thread size and pitch of the screw cap threads and the size of the area of the flexible drug reservoir 206 that is compressed when the screw cap 202 is rotated relative to manifold 208. The accuracy of the dose will depend upon the thread pitch, tolerances on the parts, and the uniformity with which the flexible reservoir 206 is compressed by the screw cap 202.
In embodiments where reservoir 206 includes a first compartment storing a liquid diluent that is stacked on top of (i.e., located distal to) a second compartment storing a lyophilized drug powder, compression of reservoir 206 generates sufficient positive pressure within the first compartment to break a frangible seal between the first and the second compartment. When the frangible seal is broken, the diluent flows from the first compartment into the second compartment to mix with the lyophilized drug powder stored in the second compartment. The mixture of the diluent with the lyophilized drug powder creates a reconstituted liquid drug mixture that is then expelled from the second compartment and into the patient's body along the fluid path described previously.
Screw cap 202 may include a lock (not shown) that may take the form of, for example, a spring-loaded pin. The lock, when engaged, prevents the cap 202 from rotating with respect to the manifold 208. In some cases, reservoir 206 may hold only enough secondary drug for a single dose—in such cases, the user may rotate cap 202 until it rotates no further with every use. After every such use, the reservoir 206 will need to be replaced or re-filled. In some cases, reservoir 206 may hold enough secondary drug for multiple doses—in such cases, the user may rotate cap 202 partially with every dose, and optionally engage the lock between doses to prevent the cap 202 from rotating further. The user may also rotate the cap 202 by different amounts to administer different amounts of secondary drug. The cap 202 and/or external surface of manifold 208 may also include markings that indicate to a user how far he or she should turn the cap 202 in order to administer a certain amount of secondary drug. For instance, the markings may indicate that a half-rotation (180°) or full-rotation (360°) of cap 202 relative to manifold 208 will result in a dose of 1 unit of secondary drug.
Valve 226 may be configured to open only when compression of the drug reservoir 206 generates sufficient positive pressure of the secondary drug. The cracking pressure of valve 226 may be tailored to be high enough that it prevents the secondary drug from being dispensed due to environmental changes, such as heating and cooling of thermoplastic parts, and/or atmospheric pressure changes. The valve also prevents backflow of liquid into reservoir 206. During storage, use, or filling, the secondary drug may come into fluid contact with various surfaces of device assembly 200, such as valve 226, stopper 230, and the inside surfaces of fluid channel 232, hub-mate septum 234, double-staked needle 214, hub septum 218, secondary drug channel 238, lumen 220, and through-hole 228. These surfaces may be made from or coated with drug-compatible materials, such as fluoroelastomer (FKM), chlorobutyl bromobutyl, silicone, or other such elastomers.
Table 1 below provides an exemplary set of parameters for assembly 200.
mm2
Since assembly 200 utilizes the same lumen 220 for delivery of both the primary and the secondary drug, there is a volume of space within infusion set hub 216 in which the two drugs may mix. This volume of space includes the volume where secondary drug channel 238 intersects with the drug channel carrying primary drug supplied by tube 222, as well as the volume within lumen 220. In some embodiments, it may be advantageous to minimize the volume of this space by making the fluid channels small at this union. With appropriate design (e.g., with channels having less than 0.015 inches inner diameter), the total volume of space shared by the primary and the secondary drug may be kept to less than three microliters.
For both assembly 200 and assembly 400, to preserve the sterility of the secondary drug stored in reservoir 206, it will typically be advantageous to maintain hub-mate septum 234 in an un-pierced state during storage. However, for ease of use and/or assembly, the drug-delivery device assembly may be packaged in a way that positions the distal end of double-pointed needle 214 directly below hub-mate septum 234. An exemplary set of user steps for piercing hub-mate septum 234 and for attaching a drug-delivery device assembly to an infusion set hub is depicted in
As illustrated in
As illustrated in
As illustrated in
As illustrated in
As illustrated in
As illustrated in
In the embodiments described so far, the drug-delivery device assembly is operated manually; that is, the user is responsible for manually actuating the assembly to deliver a dose of the secondary drug. However, in other embodiments, the assembly may also be operated automatically to, for example, dispense the secondary drug in response to a wireless signal from an external device, such as a glucose monitor or a mobile device that is receiving blood glucose values from a glucose monitor.
An example of one such embodiment is illustrated in
Referring to
When assembled, piston plate 822 may directly abut proximal surface 824 as shown in
As best seen in
One end of torsion spring 812 (e.g., the central end) is attached to screw cap 802 (potentially via a tab or spindle that protrudes proximally from the proximal surface of screw cap 802), while the other end of torsion spring 812 (e.g., the external end) is attached to an internal surface of nut 814. When assembled, torsion spring is held in a pre-loaded, coiled state by a release mechanism controlled by PCB 808. This release mechanism (not shown) may take the form of a fuse pin that prevents torsion spring 812 from uncoiling—the PCB 808 may release the release mechanism by using stored energy from battery 810 to heat and melt the fuse pin, thus releasing torsion spring 812 and allowing it to uncoil. Alternatively, the release mechanism may take the form of a mechanical micro-switch that acts as a latch to hold the torsion spring 812 in place—when the micro-switch is moved, the torsion spring 812 is unlatched and allowed to uncoil. In yet other embodiments, the release mechanism may take the form of an actuated gear that can control the extent to which torsion spring 812 is allowed to uncoil. Other release mechanisms known in the art may also be used to hold the torsion spring 812 in its pre-loaded, coiled state until released by PCB 808. PCB 808 may trigger the release mechanism in response to an instruction to administer some or all of the secondary drug in reservoir 206. This instruction may be based on a wireless signal received from an external device (e.g., a smartphone or glucose monitor), based on the push of a button situated on drug-delivery device assembly 200, and/or based on internal logic programmed or embodied on PCB 808.
When the PCB 808 triggers the release mechanism, the uncoiling of the pre-loaded torsion spring 812 causes nut 814 to rotate about longitudinal axis 826 relative to screw cap 802. Since piston 816 is prevented from rotating relative to screw cap 802 by the interface between piston rod 818 and anti-rotation pocket 806, nut 814 also rotates relative to piston 816. Rotation of nut 814 relative to piston 816 causes piston 816 to translate in the proximal direction along longitudinal axis 826 due to the aforementioned engagement between the external screw threads on piston rod 818 and the internal screw threads in opening 820. When the piston 816 translates in the proximal direction, it compresses drug reservoir 206, thus dispensing the secondary drug along the previously-described fluid pathway into the patient. In this way, screw cap sub-assembly 800 allows the drug-delivery device assembly to automatically dispense the secondary drug (e.g., in response to a wireless instruction or signal from an external device) without requiring the user to manually actuate or twist the screw cap.
Although
Torsion spring 1112 includes a tab 1113 that extends from a central end of spring 1112. Tab 1113 is attached to a central spindle portion 1103 of screw cap 1102. The other, external end of spring 1112 is attached to an interior surface of nut 1114. The external surface 1105 of nut 1114 includes external screw threads that engage with internal screw threads disposed on interior surface 1101 of pocket 1104. The engagement between these screw threads causes nut 1114 to translate in the proximal or distal direction when nut 1114 is rotated relative to screw cap 1102 about longitudinal axis 1126.
Similar to the screw top assembly 800 described herein, the torsion spring 1112 is held in a pre-loaded, coiled state by a release mechanism controlled by PCB 1108. This release mechanism may take the form of any of the release mechanisms described above in relation to screw top assembly 800. When the PCB 1108 triggers the release mechanism, the uncoiling of the pre-loaded torsion spring 1112 causes nut 1114 to rotate about longitudinal axis 1126 relative to screw cap 1102. Rotation of nut 1114 relative to screw cap 1102 causes nut 1114 to translate in the proximal direction along longitudinal axis 1126 due to the aforementioned engagement between the external screw threads on surface 1105 of nut 1114, and the internal screw threads on internal surface 1101 of pocket 1104. When the nut 1114 translates in the proximal direction, a proximal surface 1124 of nut 1114 compresses drug reservoir 206 (not shown), thus dispensing the secondary drug along the previously-described fluid pathway into the patient. In this way, screw cap sub-assembly 1100 also allows the drug-delivery device assembly to automatically dispense the secondary drug (e.g., in response to a wireless instruction or signal from an external device) without requiring the user to manually actuate or twist the screw cap.
Referring to
Referring again to
In the illustrated embodiment, the manifold 122 also includes features that facilitate delivering the secondary drug continuously to a patient over a relatively long period. Generally, these features include one or more resistance channels 142 (illustratively, three resistance channels 142) that carry a motion-inhibiting or resistance medium (shown elsewhere), such as a high-viscosity liquid/gel for example. The high-viscosity liquid may be Newtonian having a constant velocity, such as glycerol for example. The high-viscosity liquid may be thixotropic wherein the viscosity decreases in shear. An example of a thixotropic liquid is a medical-grade “grease”, such as a grease manufactured by Nye Lubricants (Fairhaven, Mass.). These optional features are described in further detail below. In other embodiments, the manifold 122 does not include such resistance channels configured to slow drug delivery.
The drug-delivery device assembly 110 further includes a plunger assembly 144 that is movably coupled to the manifold 122. Generally, the plunger assembly 144 may include any appropriate drug-compatible materials, such as FKM, chlorobutyl, bromobutyl, or silicone. The plunger assembly 144 includes a plunger base 146 and a drug plunger 148, and one or more resistance plungers 150 (illustratively, three resistance plungers 150) extend proximally from the plunger base 146. The drug plunger 148 and the resistance plungers 150 are movable together with the plunger base 146. The drug plunger 148 is movably and sealingly received in the drug reservoir 136 of the manifold 122. As such and as described in further detail below, the drug plunger 148 is proximally movable in the drug reservoir 136 to force the secondary drug from the drug reservoir 136, through the manifold drug channel 132, through the infusion hub 102, and into the patient's body together with any of the primary drug that is also present in the infusion hub 102. The resistance plungers 150 are movably and sealingly received in the resistance channels 142. As such and as described in further detail below, the resistance plungers 150 are proximally movable in the resistance channels 142 to move the resistance medium in the resistance channels 142, and the resistance medium thereby provides resistance to movement of the plunger assembly 144 relative to the manifold 122. In some embodiments, the resistance provided by the resistance medium facilitates delivering secondary drugs continuously to a patient over a relatively long time period.
With continued reference to
In some embodiments, the drug-delivery device assembly 110 also includes a detachable or releasable locking mechanism (not shown) for initially holding the biasing member 152 in a loaded state. Such mechanisms may take a variety of forms. In one example, a locking mechanism includes a detachable pin that extends through the cover 154 and into the plunger assembly 144 to hold the biasing member 152 in a loaded state between the cover 154 and the plunger assembly 144. In another example, the cover 154 includes tabs that lock to corresponding tabs on the top portion of the plunger assembly 144 to hold the biasing member 152 in a loaded state. When the cover 154 is rotated with respect to the biasing member 152, the interlocking tabs are freed thereby releasing the biasing member 152.
One or more characteristics of the biasing member 152, the plunger assembly 144, the manifold 122, the resistance medium 156, and the secondary drug 155 may be selected to provide a desired delivery duration and/or delivery rate of the secondary drug 155 to the patient. These characteristics include, for example, the elastic constant of the biasing member 152, the cross-sectional area and length of the resistance channels 142, the number of resistance plungers 150 and resistance channels 142, the viscosity of the resistance medium 156, the cross-sectional area of the drug reservoir 136, the viscosity of the secondary drug 155, and the cross-sectional area of the manifold drug channel 132. In some embodiments, one or more characteristics may be configured such that the biasing member 152 moves away from the loaded state and toward the unloaded state at a substantially constant rate (for example, constant to within +/−20 percent). For example, the cross-sectional area of the input channel portion 158 may be relatively small compared to the cross-sectional areas of the intermediate channel portion 162 and the output channel portion 160. In these embodiments, the resistance provided by the resistance channels 142 and the resistance medium 156 is largely caused by the input channel portions 158. As the biasing member 152 moves from the loaded state and towards the unloaded state, the resistance plunger 150 moves the resistance medium 156 through the input channel portion 158, the amount of the resistance medium 156 in the input channel portion 158 decreases, and the resistance decreases in a substantially linear manner. Meanwhile, the force exerted by the biasing member 152 decreases in a substantially linear manner. As such, the biasing member 152 may move away from the loaded state and toward the unloaded state at a substantially constant rate, and the secondary drug 155 may be delivered at a substantially constant rate.
In one example, the resistance channels have a round cross-section and contain a viscous, incompressible, Newtonian resistance medium that moves in laminar flow. In this example, movement of the plunger assembly 144, driven by the spring force, is governed by Poiseuille's equation. The flow of drug out of the drug reservoir is given by this equation:
Q=(R2k)/(N8μ)
where Q is the flow rate of the drug out of the drug reservoir, R is the radius of the resistive channel, k is the spring force, N is the number of resistive channels, and μ is the viscosity of the damping medium. When R, k, N and μ are constants, the flow rate Q of the drug will likewise be constant.
In another example, a constant delivery rate is facilitated by limiting the unloading of the biasing member 152. For example, the biasing member 152 may have an unloading distance over which the biasing member 152 moves from a fully-loaded state to a fully-unloaded state, but the drug-delivery device assembly 110 may be designed to operate through fifty percent (or some other suitable percentage) of that range, so that the biasing member 152 moves only fifty percent of the unloading distance during use. As such, the force exerted by the biasing member 152 may remain more constant in use, the biasing member 152 may move away from the loaded state and toward the unloaded state at a substantially constant rate, and the secondary drug 155 may be delivered at a substantially constant rate.
The drug-delivery device assembly 110′ also includes a flexible drug reservoir 136′ carried within the upper manifold portion 126′, and the flexible drug reservoir 136′ carries the secondary drug 155′. The flexible drug reservoir 136′ may be made from a thin, flexible, drug-compatible film, such as COP, COC, HDPE, and/or PCTFE. Other materials may also be used, depending upon the secondary drug 155′ carried therein. The flexible drug reservoir 136′ includes an open proximal side 165′ to facilitate (1) initially receiving the secondary drug 155′ via a proximally-extending fill port 166′ (which is disposed distally relative to the recessed upper surface portion 164′ of the infusion hub 102 and receives a stopper 168′ after filling the flexible drug reservoir 136′); and (2) delivering the secondary drug 155′ to the manifold drug channel 132′ of the lower manifold portion 124′ and ultimately the patient (when the biasing member 152′ moves from a loaded state and toward an unloaded state to move the plunger assembly 144′ proximally and compress the flexible drug reservoir 136′).
The manifold 122′ also includes features that facilitate delivering the secondary drug 155′ to a patient at a substantially constant rate. More specifically, each input channel portion 158′ of the upper manifold 122′ includes a cross-sectional area (for example, a circular area) that increases in the proximal direction. As a resistance plunger 150′ moves proximally in such a tapering input channel portion 158′, the distance between the resistance plunger 150′ and the wall of the input channel portion 158′ increases. Tendrils of the resistance medium 156′ around the resistance plunger 150′ increase in thickness, and the shear stress around the resistance plunger 150′ decreases. This decreases the resistance force applied to the plunger assembly 144′, which compensates for an increasing shear stress applied to the resistance plunger 150′ due to its increasing contact length against the resistance medium 156′. The decreasing resistance force also compensates for a decreasing force exerted by the biasing member 152′ as it moves from a loaded state (for example, as shown in
The embodiments of the drug-delivery device assemblies 110, 110′ described above include drug reservoirs and resistance channels that are arranged in parallel to each other. In some cases, parallel arrangements of drug reservoirs and resistance channels may be advantageous for one or more of the following reasons: (1) such arrangements facilitate providing a low-profile drug-device delivery assembly; (2) such arrangements provide by decoupling the size and location of the resistance channels from those of the drug reservoir; and (3) such arrangements permit the resistance medium to be gradually discharged from the output channel portions. The resulting decrease in shear stress may compensate for the decrease of the force exerted by the biasing member, and a drug-delivery device assembly may thereby deliver the secondary drug to a patient at a substantially constant rate. Alternatively, in some embodiments reservoirs and resistance channels of drug-delivery device assemblies are arranged in series with each other. Exemplary embodiments of such drug-delivery device assemblies are described in further detail below.
The following components of the drug-delivery device assembly 110″ are shown in
The biasing member 152″ may move from a loaded state (for example, as shown in
In some embodiments, the infusion hub 102″ and the drug-delivery device assembly 110″ may advantageously provide a low-profile and simple structure for delivering a relatively low volume dose of the secondary drug 155″. In these embodiments, the biasing member 152″ may move over a relatively small portion of its unloading distance to deliver the dose of the secondary drug 155″. The force exerted by the biasing member 152″ may remain substantially constant over such a distance, and the secondary drug 155″ is thereby delivered at a substantially constant rate.
The following components of the drug-delivery device assembly 110′″ are shown in
The biasing member 152′″ may be, for example and as illustrated in
The biasing member 152′″ may move from a loaded state (for example, as shown in
In some embodiments, drug-delivery device assemblies according to the present disclosure may be used by patients that are not on a course of infusion treatment (that is, without an infusion hub). In these embodiments, drug-delivery device assemblies may be used with an adapter or provided with a needle or cannula to be inserted directly into the subcutaneous space of the patient.
While embodiments of the invention have been described as having exemplary designs, the embodiments of the present disclosure may be further modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the disclosed embodiments using its general principles.
This application claims priority to U.S. Provisional Application No. 62/743,706, filed Oct. 10, 2018 (Attorney Docket No. P21817), and U.S. Provisional Application No. 62/865,340, filed Jun. 24, 2019 (Attorney Docket No. P22173), the disclosures of which are hereby expressly incorporated by reference herein in their entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2019/055127 | 10/8/2019 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62865340 | Jun 2019 | US | |
| 62743706 | Oct 2018 | US |
